FGF23 and hypophosphatemia: Based on clinical evidence obtained from patients after kidney transplantation, the use of rapamycin, an mTORC1 inhibitor, has been shown to cause hypophosphatemia associated with the impaired renal reabsorption of Pi20,21; however, this has not been associated with alterations in FGF23 levels20.